Cart
sales@molnova.com
SRX3177
CAS No. 2241237-51-2
SRX3177( —— )
Catalog No. M36306 CAS No. 2241237-51-2
SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 208 | In Stock |
|
| 5MG | 160 | In Stock |
|
| 10MG | 240 | In Stock |
|
| 25MG | 408 | In Stock |
|
| 50MG | 550 | In Stock |
|
| 100MG | 784 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSRX3177
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
-
DescriptionSRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ), <2.5 nM (CDK4), 3.3 nM (CDK6), respectively. SRX3177 exerts broad cytotoxic activity against cancer cells, but acts friendly with normal epithelial cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain | PI3K | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241237-51-2
-
Formula Weight584.69
-
Molecular FormulaC31H32N6O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (42.76 mM; Ultrasonic )
-
SMILESC(N(C)C)(=O)C=1N(C=2C(C1)=CN=C(NC3=CC=C(C=C3)C=4C5=C(SC4)C(=O)C=C(O5)N6CCOCC6)N2)C7CCCC7
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Burgoyne AM, et al. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020 Jul 28;6(1):49.?
molnova catalog
related products
-
GSK046
GSK046 is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins(IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively).
-
BRD7-IN-1
BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), forms PROTAC VZ185 via linkage to a VHL ligand, demonstrating potent activity against BRD7/9 with DC50 values of 4.5 and 1.8 nM, respectively .
-
BRD4-BD1-IN-2
BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.
